Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK. Schleiss MR, et al. Among authors: orlinger kk. Clin Vaccine Immunol. 2017 Jan 5;24(1):e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan. Clin Vaccine Immunol. 2017. PMID: 27795301 Free PMC article.
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
Schwendinger M, Thiry G, De Vos B, Leroux-Roels G, Bruhwyler J, Huygens A, Ganeff C, Buchinger H, Orlinger KK, Pinschewer DD, Monath TP, Lilja AE. Schwendinger M, et al. Among authors: orlinger kk. J Infect Dis. 2022 Apr 19;225(8):1399-1410. doi: 10.1093/infdis/jiaa121. J Infect Dis. 2022. PMID: 32313928 Free PMC article. Clinical Trial.
Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.
Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH. Penaloza MacMaster P, et al. Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26. Vaccine. 2017. PMID: 27899229 Free PMC article.
Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, Berka U, El-Gazzar A, Kiefmann B, Schulha SC, Raguz J, Habbeddine M, Scheinost M, Qing X, Lauterbach H, Matushansky I, Pinschewer DD, Orlinger KK. Schmidt S, et al. Among authors: orlinger kk. Oncoimmunology. 2020 Sep 15;9(1):1809960. doi: 10.1080/2162402X.2020.1809960. Oncoimmunology. 2020. PMID: 33457095 Free PMC article.
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack.
Bonilla WV, Kirchhammer N, Marx AF, Kallert SM, Krzyzaniak MA, Lu M, Darbre S, Schmidt S, Raguz J, Berka U, Vincenti I, Pauzuolis M, Kerber R, Hoepner S, Günther S, Magnus C, Merkler D, Orlinger KK, Zippelius A, Pinschewer DD. Bonilla WV, et al. Among authors: orlinger kk. Cell Rep Med. 2021 Mar 3;2(3):100209. doi: 10.1016/j.xcrm.2021.100209. eCollection 2021 Mar 16. Cell Rep Med. 2021. PMID: 33763654 Free PMC article.
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.
Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, Schlienger K, Berka U, Raguz J, Ahmadi-Erber S, Schippers T, Stemeseder F, Pinschewer DD, Matushansky I, Orlinger KK. Lauterbach H, et al. Among authors: orlinger kk. Front Oncol. 2021 Oct 14;11:732166. doi: 10.3389/fonc.2021.732166. eCollection 2021. Front Oncol. 2021. PMID: 34722273 Free PMC article. Review.
22 results